Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) fair value

ACCE thesis

Takeda manufactures oncology, gastroenterology, and rare disease treatments, with major franchises in blood disorders (Adcetris, Ninlaro) and inflammatory bowel disease (Entyvio). The company has a structural advantage in rare disease through its 2018 Shire acquisition, which gave it a portfolio of niche, high-margin therapies with limited competition and pricing power. Revenue growth of 10.2% masks uneven execution: oncology faces biosimilar pressure on older drugs, but the rare disease segment is expanding faster and commands gross margins above 70%. The key near-term catalyst is the FDA decision on solanezumab for Alzheimer's disease, expected in late 2024, which could unlock a new indication for an existing asset and validate Takeda's neurology pivot. At a forward PE of 35.3 with negative ROE, the market is pricing in either significant margin compression or a need to prove that rare disease growth and pipeline productivity can offset patent cliffs in legacy oncology, neither of which is assured at current valuation.